Skip to content

US · TARA · BIOTECHNOLOGY

Protara Therapeutics, Inc. (TARA) intrinsic value and stock valuation

$2.28as of 2026-11-21 · Mkt cap 224.82M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Protara Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values TARA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TARA’s statements →

Protara Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York City, NY 10010 protaratx.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-57.44M
20122025
Free cash flow
-$-56.46M
20122025
Total equity
$196.4M-0.3% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-64.55M-$-49.15M-$-43.61M-$-67.06M-$-47.49M
Net income-$-57.44M-$-44.6M-$-40.42M-$-65.95M-$-47.25M
EPSd-$-1.34M-$-2.17M-$-3.57M-$-5.86M-$-4.21M
Operating cash flow-$-56.37M-$-35.81M-$-37.56M-$-26.46M-$-34.5M
Capital expenditure-$-90K-$-60K-$-40K-$-120K-$-600K
Free cash flow-$-56.46M-$-35.87M-$-37.6M-$-26.58M-$-35.1M
Total assets$209.5M$181.5M$79M$113.3M$172.6M
Total debt$3.36M$4.48M$5.47M$6.38M$7.24M
Net debt-$-46.3M-$-158.31M-$-34.12M-$-17.74M-$-28.48M
Total equity$196.4M$167.1M$68.3M$102.1M$161.9M
Cash and short-term investments$155.6M$170.3M$65.6M$84.4M$91.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$360K$0.00$340K$0.00$0.00
Gross profit-$-360K$0.00-$-340K$0.00$0.00
Research and development expenses$42.6M$31.7M$24.8M$16.8M$21.1M
Selling, general and administrative expenses$21.9M$17.5M$18.6M$20.7M$26.4M
Other expenses-$-360K$0.00-$-140K$29.5M$0.00
Operating expenses$64.2M$49.2M$43.3M$67.1M$47.5M
Cost and expenses$64.6M$49.2M$43.6M$67.1M$47.5M
Interest income$6.33M$4.13M$2.73M$1.11M$240K
Interest expense$0.00$0.00$0.00$1.14M$1.74M
Depreciation and amortization$360K$330K$340K$250K$120K
Ebitda-$-57.08M-$-44.26M-$-40.08M-$-64.57M-$-45.4M
Operating income-$-64.55M-$-49.15M-$-43.61M-$-67.06M-$-47.49M
Total other income/expenses, net$7.11M$4.56M$3.19M$1.11M$240K
Income before tax-$-57.44M-$-44.6M-$-40.42M-$-65.95M-$-47.25M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-57.44M-$-44.6M-$-40.42M-$-65.95M-$-47.25M
Weighted average shares outstanding$42.8M$20.6M$11.3M$11.3M$11.2M
Weighted average diluted shares outstanding$42.8M$20.6M$11.3M$11.3M$11.2M
Balance sheet
20252024202320222021
Cash and short-term investments$155.6M$170.3M$65.6M$84.4M$91.2M
Net receivables$1.26M$0.00$240K$490K$630K
Inventory$0.00$0.00$0.00$1.16M$0.00
Total current assets$159.5M$172.2M$68.7M$86.2M$93.1M
Property, plant and equipment, net$3.93M$5.28M$6.56M$7.87M$8.89M
Goodwill and intangible assets$2.93M$3.25M$2.66M$80K$29.5M
Long-term investments$42.3M$0.00$0.00$17.9M$39.5M
Total non-current assets$50M$9.3M$10.3M$27.1M$79.5M
Total assets$209.5M$181.5M$79M$113.3M$172.6M
Accounts payable$3.47M$4.43M$2.43M$1.59M$950K
Short-term debt$1.24M$1.12M$980K$920K$850K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$10.9M$11M$6.15M$5.74M$4.3M
Long-term debt$2.12M$3.36M$4.48M$5.47M$6.38M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.12M$3.36M$4.48M$5.47M$6.38M
Capital lease obligations$3.36M$4.48M$5.47M$6.38M$7.24M
Total liabilities$13.1M$14.3M$10.6M$11.2M$10.7M
Common stock$50K$40K$10K$10K$10K
Retained earnings-$-302.42M-$-244.98M-$-200.38M-$-159.96M-$-94.01M
Accumulated other comprehensive income (loss)$90K$0.00-$-30K-$-690K-$-210K
Total equity$196.4M$167.1M$68.3M$102.1M$161.9M
Total investments$148.2M$7.49M$26M$78.1M$95M
Total debt$3.36M$4.48M$5.47M$6.38M$7.24M
Net debt-$-46.3M-$-158.31M-$-34.12M-$-17.74M-$-28.48M
Cash flow statement
20252024202320222021
Net income-$-57.44M-$-44.6M-$-40.42M-$-65.95M-$-47.25M
Depreciation and amortization$360K$330K$340K$250K$120K
Stock-based compensation$3.83M$4.12M$6.09M$6.69M$10.4M
Change in working capital-$-2.94M$4.01M-$-4.14M$540K$530K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-870K$1.38M$850K$630K$40K
Net cash provided by operating activities-$-56.37M-$-35.81M-$-37.56M-$-26.46M-$-34.5M
Investments in property, plant and equipment-$-90K-$-60K-$-40K-$-120K-$-600K
Acquisitions, net$0.00$0.00$0.00-$-20K$100K
Net cash used for investing activities-$-139.49M$19.2M$53.1M$15M-$-98.19M
Common stock issued$82.9M$136M$0.00$0.00$0.00
Common stock repurchased$0.00$0.00-$-90K-$-90K-$-230K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$82.7M$139.9M-$-90K-$-90K-$-230K
Net change in cash-$-113.14M$123.2M$15.5M-$-11.6M-$-132.92M
Cash at end of period$50.4M$163.5M$40.3M$24.9M$36.5M
Operating cash flow-$-56.37M-$-35.81M-$-37.56M-$-26.46M-$-34.5M
Capital expenditure-$-90K-$-60K-$-40K-$-120K-$-600K
Free cash flow-$-56.46M-$-35.87M-$-37.6M-$-26.58M-$-35.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Protara Therapeutics, Inc.

        Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.

        CEO
        Jesse Shefferman
        Employees
        51
        Beta
        1.48

        Explore

        Frequently asked questions

        What is the intrinsic value of Protara Therapeutics, Inc. (TARA)?

        InvestorsCraft does not currently publish an intrinsic value for TARA. How the IC value is calculated.

        Is TARA undervalued?

        InvestorsCraft does not publish an undervaluation signal for TARA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.